The challenge of prognostic markers in pleural mesothelioma

被引：6

作者：

Imperatori, Andrea ^{[1
]}

Castiglioni, Massimo ^{[1
]}

Mortara, Lorenzo ^{[2
]}

Nardecchia, Elisa ^{[1
]}

Rotolo, Nicola ^{[1
]}

机构：

[1] Univ Insubria, Ctr Thorac Surg, Dept Surg & Morphol Sci, I-21100 Varese, Italy

[2] Univ Insubria, Dept Biotechnol & Life Sci, I-21100 Varese, Italy

来源：

JOURNAL OF THORACIC DISEASE | 2013年 / 5卷 / 03期

关键词：

Malignant pleural mesothelioma (MPM); prognostic factors; translational research; MALIGNANT MESOTHELIOMA; SERUM; OSTEOPONTIN;

D O I：

10.3978/j.issn.2072-1439.2013.06.12

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Malignant pleural mesothelioma (MPM) is a very aggressive tumor, highly resistant to chemo- and radio-therapy. Treatment of MPM patients is often disappointing, regardless of the modality used. Inter-individual variability of response to multimodal treatment remains a challenge and generally the MPM prognosis continues to be poor. Knowledge of predicting factors of outcome is currently insufficient; therefore, it would be highly desirable to find specific prognostic markers for MPM. Translational research projects are to be implemented.

引用

页码：205 / 206

页数：2

共 16 条

[11] Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma [J].

Pass, Harvey I. ;

Levin, Stephen M. ;

Harbut, Michael R. ;

Melamed, Jonathan ;

Chiriboga, Luis ;

Donington, Jessica ;

Huflejt, Margaret ;

Carbone, Michele ;

Chia, David ;

Goodglick, Lee ;

Goodman, Gary E. ;

Thornquist, Mark D. ;

Liu, Geoffrey ;

de Perrot, Marc ;

Tsao, Ming-Sound ;

Goparaju, Chandra .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (15) :1417-1427

[12] Asbestos exposure, pleural mesothelioma, and serum osteopontin levels [J].

Pass, HI ;

Lott, D ;

Lonardo, F ;

Harbut, M ;

Liu, ZD ;

Tang, NM ;

Carbone, M ;

Webb, C ;

Wali, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (15) :1564-1573

[13] Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/Mesothelin increases its potential as a useful serum tumor marker for mesothelioma [J].

Shiomi, Kazu ;

Hagiwara, Yoshiaki ;

Sonoue, Kouji ;

Segawa, Tatsuya ;

Miyashita, Kazuya ;

Maeda, Masahiro ;

Izumi, Hiroshi ;

Masuda, Kimihiko ;

Hirabayashi, Masataka ;

Moroboshi, Takao ;

Yoshiyama, Takashi ;

Ishida, Atsuko ;

Natori, Yuji ;

Inoue, Akira ;

Kobayashi, Masashi ;

Sakao, Yukinori ;

Miyamoto, Hideaki ;

Takahashi, Kazuhisa ;

Hino, Okio .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1431-1437

[14]

Steele JPC, 2000, THORAX, V55, P725

[15]

SUGARBAKER DJ, 1991, J THORAC CARDIOV SUR, V102, P10

[16] Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J].

Vogelzang, NJ ;

Rusthoven, JJ ;

Symanowski, J ;

Denham, C ;

Kaukel, E ;

Ruffie, P ;

Gatzemeier, U ;

Boyer, M ;

Emri, S ;

Manegold, C ;

Niyikiza, C ;

Paoletti, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2636-2644

← 1 2 →